US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Adicet Bio, Inc.

< Previous 1 2 3 4 Next >
News headline image
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Announces Reverse Stock Split
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
News headline image
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Tickers ACET
< Previous 1 2 3 4 Next >